Samsrita Labs

Why is Samsrita Labs Ltd falling/rising?

As of 17-Jun, Samsrita Labs Ltd's stock price is at 14.80, reflecting a 3.14% decrease. The stock has significantly underperformed against the Sensex, showing declines over various time frames and a drop in investor participation, indicating a bearish trend.

As of 17-Jun, Samsrita Labs Ltd's stock price is falling, currently at 14.80, which reflects a decrease of 0.48 or 3.14%. The stock has underperformed significantly compared to the benchmark Sensex, which has gained 4.29% over the past week, while Samsrita Labs has declined by 3.58%. Over the past month, the stock has also decreased by 5.43%, contrasting with the Sensex's increase of 2.55%. Year-to-date, the stock is down 28.71%, while the Sensex has only fallen by 9.46%. <BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also decreased, with a delivery volume of 5.1k on June 16, which is down by 50.24% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors, contributing to the stock's downward movement. Overall, these factors indicate that Samsrita Labs Ltd is experiencing a decline in its stock price.

Which are the latest news on Samsrita Labs?

What does Samsrita Labs do?

Samsrita Labs Ltd is a micro-cap company in the healthcare services industry, previously known as Dr Habeebullah Life Sciences Limited. As of March 2026, it reported net sales and profit of 0 Cr, with a market cap of INR 32 Cr.

Overview: <BR>Samsrita Labs Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Samsrita Labs Ltd was initially incorporated as 'Dr Habeebullah Life Sciences Limited' in 1996. The company underwent a name change to Samsrita Labs Ltd on October 13, 2022. The latest quarterly results reported net sales and net profit of 0 Cr for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 32 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: -76.63% <BR>Price to Book: 2.81<BR><BR>Contact Details: <BR>Address: Sy No 36 Chintalmet X Roads, Upperpally Attapur Rajendra Ng Hyderabad Telangana : 500048 <BR>Tel: 91-90300 57370 <BR>Email: pcproductsindia@gmail.com <BR>Website: https://drhlsl.com

How big is Samsrita Labs?

As of 10th June, Samsrita Labs Ltd has a market capitalization of 32.00 Cr, classifying it as a Micro Cap company, with Net Sales of 0.02 Cr and a Net Profit loss of 7.97 Cr over the latest four quarters. Shareholder's Funds are 11.97 Cr, and Total Assets are 15.57 Cr as of March 2025.

As of 10th June, Samsrita Labs Ltd has a market capitalization of 32.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.02 Cr. However, it experienced a loss of 7.97 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's Funds are reported at 11.97 Cr, while Total Assets amount to 15.57 Cr.

Who are in the management team of Samsrita Labs?

The management team of Samsrita Labs includes K Krishnam Raju (Chairman & Wholetime Director), K.N.V Narendra Kumar (Whole Time Director & CFO), and five Independent Directors: B Suryaprakash Rao, Aakanksha, Ramamohan Reddy Yarragudi, A.S.S.V. Srinivas, and Deepa Dudani (Company Secretary & Compliance Officer). They guide the company's strategic direction and ensure regulatory compliance.

The management team of Samsrita Labs includes the following individuals:<BR><BR>1. K Krishnam Raju - Chairman & Wholetime Director<BR>2. K.N.V Narendra Kumar - Whole Time Director & CFO<BR>3. B Suryaprakash Rao - Independent Director<BR>4. Aakanksha - Independent Director<BR>5. Ramamohan Reddy Yarragudi - Independent Director<BR>6. A.S.S.V. Srinivas - Independent Director<BR>7. Deepa Dudani - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

Who are the peers of the Samsrita Labs?

Samsrita Labs' peers include Shree Pacetronix, Bandaram Pharma, Amkay Products, and others, with varying management risks and growth rates. Shree Pacetronix leads in 1-year returns at 66.87%, while Samsrita Labs has a return of -26.93%.

Peers: The peers of Samsrita Labs are Shree Pacetronix, Bandaram Pharma, Amkay Products, KMS Medisurgi, N G Industries, GKB Ophthalmics, Deccan Healthcar, Centenial Surgic, and Chennai Meena.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shree Pacetronix, Amkay Products, N G Industries, and Sunrest Lifescie, while Average management risk is found at KMS Medisurgi. Below Average management risk is noted at Bandaram Pharma, GKB Ophthalmics, Deccan Healthcar, and Centenial Surgic, and the rest. Growth is excellent at Sunrest Lifescie, good at Shree Pacetronix, Bandaram Pharma, GKB Ophthalmics, and Deccan Healthcar, while below average growth is seen at Amkay Products, KMS Medisurgi, N G Industries, Centenial Surgic, and the rest. Capital structure is good at Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, and the rest, while below average is noted at Bandaram Pharma, GKB Ophthalmics, Deccan Healthcar, and Centenial Surgic.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shree Pacetronix at 66.87%, while the lowest is Bandaram Pharma at -25.32%. Samsrita Labs has a 1-year return of -26.93%, which is lower than Bandaram Pharma's. Additionally, KMS Medisurgi, N G Industries, GKB Ophthalmics, Deccan Healthcar, Centenial Surgic, and Chennai Meena all have negative six-month returns.

When is the next results date for Samsrita Labs Ltd?

The next results date for Samsrita Labs Ltd is 29 May 2026.

The next results date for Samsrita Labs Ltd is scheduled for 29 May 2026.

How has been the historical performance of Samsrita Labs?

Samsrita Labs has experienced a declining trend in net sales, dropping from 2.01 Cr in March 2019 to 0.01 Cr in March 2021, alongside increasing losses, with an operating profit of -0.79 Cr in March 2021. The company's total liabilities and assets also decreased significantly during this period, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Samsrita Labs shows a declining trend in net sales and increasing losses over the years.<BR><BR>Breakdown:<BR>Samsrita Labs reported net sales of 0.01 Cr in March 2021, a significant drop from 1.43 Cr in March 2020 and 2.01 Cr in March 2019. The total operating income followed a similar trend, decreasing from 1.43 Cr in March 2020 to 0.01 Cr in March 2021. The company faced substantial losses, with an operating profit (PBDIT) of -0.79 Cr in March 2021, improving slightly from -2.03 Cr in March 2020 but still reflecting ongoing operational challenges. Profit before tax was recorded at -0.80 Cr in March 2021, compared to -2.05 Cr in the previous year, while profit after tax also showed a loss of -0.78 Cr, down from -1.98 Cr in March 2020. The company's total liabilities decreased from 27.75 Cr in March 2020 to 16.58 Cr in March 2021, with total assets also declining from 27.75 Cr to 16.58 Cr in the same period. Cash flow from operating activities remained stagnant, with no inflow or outflow reported in the last two years. Overall, the financial data indicates a challenging period for Samsrita Labs, characterized by declining revenues and persistent losses.

Is Samsrita Labs overvalued or undervalued?

As of April 25, 2023, Samsrita Labs is rated as "risky" and overvalued with a negative PE ratio of -31.10 and an EV to EBIT ratio of -33.30, indicating significant financial struggles compared to peers like MMTC and Optiemus Infra, despite a recent 34.45% return.

As of 25 April 2023, Samsrita Labs has moved from a grade of "does not qualify" to "risky." The company is currently overvalued, as indicated by its negative PE ratio of -31.10 and an EV to EBIT ratio of -33.30. Additionally, the ROCE stands at -3.04%, which further highlights the company's financial struggles.<BR><BR>In comparison to peers, MMTC has a PE ratio of 119.39 and an EV to EBITDA of -70.04, while Optiemus Infra is considered fair with a PE ratio of 82.35 and an EV to EBITDA of 48.56. The stark contrast in these ratios suggests that Samsrita Labs is not only underperforming relative to its peers but also carries significant risk. Despite a recent 34.45% return over the past year, the overall valuation metrics indicate that the stock remains overvalued in the current market context.

What is the technical trend for Samsrita Labs?

As of May 12, 2025, Samsrita Labs shows a mildly bullish trend supported by positive MACD and KST indicators, despite some short-term weakness indicated by the RSI and daily moving averages.

As of 12 May 2025, the technical trend for Samsrita Labs has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is mildly bullish, indicating a gradual strengthening. The weekly KST is mildly bullish and the monthly KST is bullish, further reinforcing the upward momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The daily moving averages are mildly bearish, which contrasts with the overall bullish sentiment. Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating potential for price expansion. Overall, the current stance is mildly bullish, driven primarily by the MACD and KST indicators, despite some mixed signals from the RSI and moving averages.

Who are the top shareholders of the Samsrita Labs?

The top shareholders of Samsrita Labs are K Krishnam Raju with 19.58%, followed by M Neela Reddy at 4.67%, and individual investors collectively holding 44.75%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Samsrita Labs include K Krishnam Raju, who holds the highest promoter share at 19.58%. Following him, the highest public shareholder is M Neela Reddy, with a holding of 4.67%. Additionally, individual investors collectively hold 44.75% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Has Samsrita Labs declared dividend?

No Dividend History Available